Spotlight on Atomoxetine in Attention-Deficit Hyperactivity Disorder in Children and Adolescentsy
- PDF / 108,362 Bytes
- 4 Pages / 504.57 x 720 pts Page_size
- 67 Downloads / 161 Views
ADIS SPOTLIGHT
ยช 2010 Adis Data Information BV. All rights reserved.
Spotlight on Atomoxetine in Attention-Deficit Hyperactivity Disorder in Children and Adolescentsy Karly P. Garnock-Jones and Gillian M. Keating Adis, a Wolters Kluwer Business, Auckland, New Zealand
Contents Abstract. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1. Pharmacological Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2. Therapeutic Efficacy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3. Tolerability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4. Pharmacoeconomic Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abstract
85 86 86 86 87
Atomoxetine (Strattera) is a selective noradrenaline (norepinephrine) reuptake inhibitor that is not classified as a stimulant, and is indicated for use in patients with attention-deficit hyperactivity disorder (ADHD). Atomoxetine is effective and generally well tolerated. It is significantly more effective than placebo and standard current therapy and does not differ significantly from, or is noninferior to, immediate-release methylphenidate; however, it is significantly less effective than the extended-release methylphenidate formulation OROS methylphenidate (hereafter referred to as osmotically released methylphenidate) and extended-release mixed amfetamine salts. Atomoxetine can be administered either as a single daily dose or split into two evenly divided doses, has a negligible risk of abuse or misuse and is not a controlled substance in the US. Atomoxetine is particularly useful for patients at risk of substance abuse, as well as those who have co-morbid anxiety or tics, or who do not wish to take a controlled substance. Thus, atomoxetine is a useful option in the treatment of ADHD in children and adolescents.
y Adapted and reproduced from Pediatr Drugs 2009; 11 (3): 203-26. The full text article[1] was reviewed by J. Graham, Department of Psychiatry, University of Dundee, Dundee, UK; D.E. Greydanus, Department of Pediatrics and Human Development, Michigan State University, Kalamazoo, Michigan, USA; F. Levy, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia. The manufacturer of the agent under review was offered an opportunity to comment on the original article during the peer review process. Changes based on any comments received were made on the basis of scientific and editorial merit. The preparation of the original article and this spotlight was not supported by any external funding.
Garnock-Jones & Keating
86
1. Pharmacological Properties The mechanism of action of atomo
Data Loading...
